Skip to main content

Table 6 Relapse free survival before and after the propensity score matched analysis (PS)

From: Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients

Characteristic

RFS univariate pre PS

RFS multivariate pre-PS

RFS univariate post PS

RFS multivariate post-PS

1 year

2 year

p

Exp B

p

1 year

2 year

p

Exp-B

p

Gender

NS

 

0.035

  

0.027

 

0.015

 Male

78.7

71

  

78.7

71

1

 

 Female

90.2

86.8

  

94.2

90.3

0.229 (IC 0.07–0.7488)

 

Age

NS

 

NS

  

NS

 

NS

 < 70 years

80.6

75

  

81.2

74.1

  

 > 70 years

87.7

82.2

  

87.7

82.2

  

KPS

NS

 

NS

  

NS

 

NS

 90–10

80.9

74.9

  

81.7

75.4

  

 70–80

82.5

74.8

  

82.5

74.8

  

Tobacco use

NS

 

NS

  

NS

 

NS

 Currently < 10 cigarettes/die

83

75.4

  

83

75.4

  

 Currently 10–20 cigarettes/die

87

77.6

  

86.5

76.6

  

 Currently > 20 cigarettes/die

78.3

73.8

  

78.3

73.7

  

 Stopped smoking > 5 years

82.5

78.7

  

81.8

77.9

  

 Never smoked

79.5

72.9

  

82.3

74.9

  

Alcohol

NS

 

NS

  

NS

 

NS

 Currently

85.8

79

  

85.7

78.7

  

 Past

76.7

63.8

  

76.7

63.8

  

 Never

78.4

76.2

  

78.7

76.3

  

Stage T

NS

 

NS

  

NS

 

NS

 T1-2

82.5

77.9

  

83.6

78.9

  

 T3-4

80.9

72.1

  

80.9

72.1

  

Stage N

NS

 

NS

  

NS

 

NS

 0

88.9

82.1

  

88.9

82.1

  

 1

91.1

85

  

91.1

85

  

 2

79.8

74.2

  

80.4

74.5

  

 3

53.3

26.7

  

26.7

26.7

  

Stage of disease

NS

 

NS

  

NS

 

NS

 II

100

100

  

100

100

  

 III

83.4

79.5

  

83.4

79.5

  

 IV

80.4

72.8

  

81

73.1

  

Site of disease

NS

 

NS

  

NS

 

NS

 Oropharynx

84.9

78.8

  

85.9

79.4

  

 Hypopharynx

84

68.5

  

84

68.5

  

 Larynx

63

63

  

63

63

  

RT technique

NS

 

NS

  

NS

 

NS

 IMRT/VMAT

76.7

69.5

  

77.5

70

  

 Helical IMRT

92.3

82.6

  

92.3

86.4

  

Type of CHT

NS

 

NS

  

NS

 

NS

 1w-CDDP

85.2

78.9

  

75.2

67.6

  

 3w-CDDP

74.3

67.5

  

85.2

78.9

  

Total CDDP/m2

NS

 

NS

  

NS

 

NS

 < 200 mg/m2

66.7

53.3

  

48

48

  

 200–250 mg/m2

85.9

85.9

  

93.3

93.3

  

 > 250 mg/m2

82.3

75.6

  

82.9

76

  

CDDP interruption

NS

 

NS

  

NS

 

NS

 Yes

79.6

76.2

   

79.8

76.3

  

 No

83.8

74.2

   

84.7

74.7

  
  1. RT radiotherapy, IMRT intensity modulated radiation therapy, CDDP cisplatin, 1w-CDDP weekly cisplatin, 3w-CDDP three weekly cisplatin